敏實集團(00425.HK)預期中期淨利減少55%至60%
格隆匯7月14日丨敏實集團(00425.HK)公佈,相較截至2019年6月30日止6個月公司擁有人應占溢利約人民幣8.94億元,公司預期截至2020年6月30日止6個月淨利將減少55%至60%。回顧期間淨利預計下降主要歸因於新型冠狀病毒疫情的爆發以及老產品降價的壓力。
於回顧期間,針對COVID-19的防疫措施對全球經濟產生深遠影響,集團回顧期間之營業額預計將因此較上年同期下滑20%至25%,從而使得集團產能利用率明顯降低。加之集團仍面臨老產品降價以及美國對中國出口產品加徵關税的壓力,預期集團毛利率較上年同期將下滑5%至7%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.